Ecophysiology of iron homeostasis in plants

In nature, iron (Fe) occurs in abundance and ranks fourth among all elements on Earth’s surface. Still, its availability to plants is reduced, once this element is in the form of hydrated oxides, which can limit plant productivity and biomass production. On the other hand, in high concentrations, this essential micronutrient for the plants can become a toxic agent, increasing the environmental contamination. Fe is necessary for the maintenance of essential processes like respiration and photosynthesis, participating in the electron transport chain and in the conversion between Fe²⁺ and Fe³⁺, being a key element for carbon dioxide (CO₂) fixation and, therefore, important for crop production of cultivated or natural species. The balance of Fe should be strictly controlled, because both its deficiency and its toxicity affect the physiological process of plants. In aerated soils Fe is present in the form of Fe³⁺, which is the oxidized form and is less available to plants, so these organisms have developed different strategies for absorption, transport and storage of Fe. Deficiency and excess of Fe correlate with local soil conditions and with the care adopted in plant nutrition during the phenological phases and/or in the course of its cultivation. In situations of excessive accumulation of Fe in tissues, an enhancement of hydroxyl radical generation (OH^?) occurs by Fenton reaction. Here, we review the nutritional, genetic and ecophysiological aspects of uptake, translocation and accumulation of Fe ions in plants growing under conditions of deficiency or toxicity of this metal.     

Erythema multiforme associated with zonisamide in a dog

This report describes a dog that developed erythema multiforme in temporal association with administration of the sulphonamide‐based anticonvulsant drug zonisamide. Similar adverse drug reactions have been associated with sulphonamide antimicrobial drugs. Caution should be exercised when prescribing this medication for dogs with known hypersensitivity to sulphonamides.     

Binding of ciprofloxacin labelled with technetium Tc 99m versus 99mTc-pertechnetate to a live and killed equine isolate of Escherichia coli

This paper describes a simple methodology for evaluating the bacterial binding of ciprofloxacin labelled with technetium Tc 99m. Using this methodology, the binding of 99mTc-ciprofloxacin by live Escherichia coli was compared with the binding of 99mTc-ciprofloxacin by killed E. coli and the binding of 99mTc-pertechnetate (99mTcO4-) by live E. coli. The antimicrobial effect of 99mTc-ciprofloxacin on E. coli was evaluated. Four groups were defined: live E. coli with 99mTc-ciprofloxacin, live E. coli with 99mTcO4 , killed E. coli with 99mTc-ciprofloxacin, and killed E. coli with 99mTcO4-. After 0, 2, and 4 h of incubation of 1 x 10(8) colony-forming units of E. coli suspended in 5 mL of sterile distilled water with 1.85 MBq of 99mTc-ciprofloxacin or 99mTcO4, 1 mL from each sample was centrifuged. The radioactivity of the bacterial pellet and that of the supernatant were measured separately, and the percentage of sample radioactivity attributable to bacterial binding was calculated. Of the 99mTc-ciprofloxacin, 3.6% to 5.9% was bound to live or killed E. coli; only 0.1% to 0.2% of the 99mTcO4- was bound to live E. coli (P < 0.0001). No significant difference in 99mTc-ciprofloxacin binding was found between live and killed E. coli (P = 0.887). An antimicrobial effect on E. coli was seen with 99mTc-ciprofloxacin: colony counts were reduced after 4 h. The small amount of 99mTc-ciprofloxacin binding and the lack of difference in binding between live and killed E. coli may limit the utility of this methodology in evaluating the presence of E. coli infection.     

Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs

Objective – To describe the use of IV and oral mycophenolate mofetil (MMF) as adjunctive therapy in 3 dogs with severe generalized myasthenia gravis.
Case Series Summary – Three dogs suffering from severe generalized myasthenia gravis as confirmed by acetylcholine antibody titers were treated with MMF as part of their treatment regimens. All 3 dogs had radiographic evidence of megaesophagus and suffered from severe regurgitation. Each dog was initially treated with pyridostigmine and supportive agents. When clinical remission was not achieved, IV MMF was administered to all dogs. Signs of clinical remission were apparent within 48 hours and all dogs were later maintained on oral MMF following resolution of regurgitation.
New or Unique Information Provided – This is the first report of the use of IV MMF as adjunctive treatment in dogs with severe generalized myasthenia gravis. Outcome was favorable in all 3 dogs and no adverse effects were noted from the MMF.     

Salty stories,fresh spaces: Lessons for aquatic protected areas from marine and freshwater experiences

相似文献